{
    "nctId": "NCT01031446",
    "briefTitle": "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 55,
    "primaryOutcomeMeasure": "Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive mammary carcinoma\n\n  * Stage IV disease\n  * Basal-like disease (triple-negative, hormone-refractory, HER2-negative)\n* No locally recurrent breast cancer\n* No symptomatic brain metastases\n\n  * Patients with a history of brain metastases are eligible provided they are clinically stable for \\> 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers\n  * Patients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers\n\nPATIENT CHARACTERISTICS:\n\n* Pre- or post-menopausal\n* European Cooperative Oncology Group (ECOG) performance status 0-1\n* Life expectancy \u2265 6 months\n* Absolute neutrophil count (ANC) \u2265 1,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Total bilirubin \u2264 1.5 times ULN (\u2264 3 times ULN in the presence of liver metastasis)\n\n  * Direct bilirubin will be measured in patients with Gilbert syndrome\n* serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) \u2264 1.5 times ULN (\u2264 3 times ULN in the presence of liver metastasis)\n* Alkaline phosphatase \u2264 3 times ULN (in the presence of liver metastasis)\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment\n* Able to swallow and retain oral medication\n* No malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel\n* No concurrent uncontrolled illness including, but not limited to, any of the following:\n\n  * Ongoing or active infection requiring parenteral antibiotics\n  * Impaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)\n  * New York Heart Association class III-IV congestive heart failure\n  * Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months\n  * Uncontrolled hypertension (systolic BP \\> 180 mm Hg or diastolic BP \\> 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)\n  * Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment \\[grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0\\])\n  * Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)\n  * Psychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary\n* No symptomatic neuropathy \u2265 grade 2\n* No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ\n* No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies\n* No history of hepatitis B or C\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from prior therapy\n* Prior total cumulative life-time dose of doxorubicin \u2264 360 mg/m\\^2 or epirubicin \u2264 640 mg/m\\^2\n* No more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)\n* At least 2 weeks since prior investigational drugs\n* At least 14 days since prior and no concurrent herbal or dietary supplements\n* At least 14 days since prior and no concurrent CYP3A4 inducers\n* At least 7 days since prior and no concurrent CYP3A4 inhibitors\n* Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry\n* No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, biologic therapy)",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}